Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ) exhibits 41.0% gross margins and -4.7% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 7.2% implied options volatility.
Sustained 41.0% gross profitability converts into -10.1% operating margin and -4.7% ROIC, outpacing sector cost of capital.
ROIC: -4.7% // GM: 41.0%YoY revenue trajectory of +4.9% paired with 9.61% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +4.9% // FCF YLD: 9.61%Altman Z-Score of 1.97 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 1.97 // F-SCORE: 7/9Trading at 24.0x trailing P/E (36.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±7.2% implied move with a 0.81 put/call ratio around $204.00 max pain.
IMPL MOVE: ±7.2% // P/C: 0.81Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -8.3% net margins.
NET MARGIN: -8.3% // D/E: 1.00x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for JAZZ & activate live FRED threshold breach alerts.